Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | PDE4A | P27815 | 3/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.34 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 3/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 2/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.33 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7816003 | 0.71 | HPGD (0.49) | RXFP1KMT2AADORA2BHPGDGAA | |
| SCHEMBL26248663 | 0.69 | ADORA2A (0.55) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7806218 | 0.65 | GAA (0.48) | ADORA2AKDM4EKMT2APDE4APDE4B | |
| SCHEMBL8177043 | 0.64 | ADORA2B (0.46) | RXFP1KDM4EPDE4AADORA2BHPGD | |
| SCHEMBL7812587 | 0.64 | SMN1; SMN2 (0.46) | RXFP1KMT2AADORA2BHPGDGAA | |
| SCHEMBL23115569 | 0.64 | SMN1; SMN2 (0.50) | RXFP1KDM4EKMT2AADORA2BHPGD | |
| SCHEMBL7809883 | 0.64 | ADORA2A (0.47) | ADORA2AKMT2APDE4APDE4BPDE4C | |
| SCHEMBL3433600 | 0.64 | SMN1; SMN2 (0.50) | RXFP1KMT2APDE4APDE4BPDE4C | |
| SCHEMBL25165796 | 0.63 | TRPA1 (0.42) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL23718338 | 0.63 | PDE4A (0.44) | ADORA2ARXFP1PDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10036066-B2 | In situ hybridization detection method | DAKO DENMARK A/S (DK) | 2018-07-31 | — | — | US | disclosed |
| US-9598720-B2 | Monomeric and polymeric linkers useful for conjugating biological molecules and other substances | DAKO DENMARK A/S (DK) | 2017-03-21 | — | — | US | disclosed |
| US-20160273035-A1 | IN SITU HYBRIDIZATION DETECTION METHOD | DAKO DENMARK A/S (DK) | 2016-09-22 | — | — | US | disclosed |
| EP-1919930-B1 | NEW NUCLEIC ACID BASE PAIRS | DAKO DENMARK AS (DK) | 2016-09-14 | — | — | EP | disclosed |
| US-9340824-B2 | Immunohistochemistry detection method | DAKO DENMARK A/S (DK) | 2016-05-17 | — | — | US | disclosed |
| US-9017992-B2 | In situ hybridization detection method | DAKO DENMARK A/S (DK) | 2015-04-28 | — | — | US | disclosed |
| EP-1910575-B1 | IMMUNOHISTOCHEMISTRY DETECTION METHOD | DAKO DENMARK AS (DK) | 2014-12-10 | — | — | EP | disclosed |
| US-20140315204-A1 | Immunohistochemistry Detection Method | DAKO DENMARK A/S (DK) | 2014-10-23 | — | — | US | disclosed |
| US-8741566-B2 | Immunohistochemistry and in situ hybridization detection method | DAKO DENMARK A/S (DK) | 2014-06-03 | — | — | US | disclosed |
| US-20140080145-A1 | Monomeric and Polymeric Linkers Useful For Conjugating Biological Molecules and Other Substances | DAKO DENMARK A/S (DK) | 2014-03-20 | — | — | US | disclosed |
| EP-1919930-A2 | NEW NUCLEIC ACID BASE PAIRS | Dako Denmark A/S (DK) | 2008-05-14 | — | — | EP | disclosed |
| EP-1920073-A2 | METHOD OF SIMULTANEOUSLY VISUALIZING MULTIPLE BIOLOGICAL TARGETS | Dako Denmark A/S (DK) | 2008-05-14 | — | — | EP | disclosed |
| EP-1910575-A2 | IMMUNOHISTOCHEMISTRY DETECTION METHOD | Dako Denmark A/S (DK) | 2008-04-16 | — | — | EP | disclosed |
| EP-1907592-A2 | MONOMERIC AND POLYMERIC LINKERS USEFUL FOR CONJUGATING BIOLOGICAL MOLECULES AND OTHER SUBSTANCES | Dako Denmark A/S (DK) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007031874-A9 | METHOD OF SIMULTANEOUSLY VISUALIZING MULTIPLE BIOLOGICAL TARGETS | DAKO DENMARK AS (DK) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007045998-A2 | NEW NUCLEIC ACID BASE PAIRS | DAKO DENMARK A/S (US) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007031874-A2 | METHOD OF SIMULTANEOUSLY VISUALIZING MULTIPLE BIOLOGICAL TARGETS | DAKO DENMARK A/S (US) | 2007-03-22 | — | — | WO | disclosed |
| WO-2007026252-A2 | IN SITU HYBRIDIZATION DETECTION METHOD | DAKO DENMARK A/S (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007023390-A2 | IMMUNOHISTOCHEMISTRY DETECTION METHOD | DAKO DENMARK A/S (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007015168-A2 | MONOMERIC AND POLYMERIC LINKERS USEFUL FOR CONJUGATING BIOLOGICAL MOLECULES AND OTHER SUBSTANCES | DAKO DENMARK A/S (US) | 2007-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080145-A1 | Monomeric and Polymeric Linkers Useful For Conjugating Biological Molecules and Other Substances | PCNA, DCLRE1A, TK1 | ADORA2A 2722/4885RXFP1 2174/4885KDM4E 4606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.